SeaStar Medical Reports 69% Revenue Growth, Advances Adult AKI Trial & Initiates Modular PMA Submission

summarizeSummary

SeaStar Medical announced Q1 2026 financial results, reporting a 69% increase in QUELIMMUNE revenue to $0.5 million and progress in its adult AKI pivotal trial and regulatory submissions, alongside a decrease in cash reserves.

check_boxKey Events

• Strong Revenue Growth

  Net revenue for Q1 2026 increased by 69% year-over-year to $0.5 million, driven by expanded adoption of the QUELIMMUNE pediatric AKI therapy, adding 7 new top-rated children's hospitals.

• Adult AKI Trial Progress

  Enrollment in the NEUTRALIZE-AKI pivotal trial for adult patients with AKI advanced, with 198 of 339 patients enrolled to date. The company aims to complete enrollment by the end of 2026.

• Initiated Modular PMA Submission

  Efforts have begun for the submission of a modular post-marketing application (PMA) to the FDA for the SCD therapy in adult AKI, which has Breakthrough Device Designation and may expedite the approval process.

• Cash Position Update

  Cash reserves decreased to $9.3 million as of March 31, 2026, down from $12.0 million at December 31, 2025, indicating continued cash burn for operations and clinical development.

auto_awesomeAnalysis

SeaStar Medical reported strong 69% year-over-year revenue growth for its QUELIMMUNE product in Q1 2026, reaching $0.5 million. This indicates positive commercial traction for its pediatric acute kidney injury (AKI) therapy. The company also made significant clinical progress, advancing enrollment in its pivotal NEUTRALIZE-AKI trial for adult patients and initiating efforts for a modular post-marketing application (PMA) submission, which could expedite FDA approval. While the net loss decreased slightly, the company's cash balance declined by $2.7 million during the quarter, highlighting continued cash burn and the ongoing need for capital, as evidenced by recent S-1/A filings.